The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.

[1]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[2]  N. Hollenberg,et al.  Literature alert , 2002 .

[3]  J. Cohn,et al.  Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT) , 2002, Circulation.

[4]  J. Cohn.  The Sympathetic Nervous System in Heart Failure , 2002, Circulation.

[5]  R. Latini,et al.  Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. , 2002, Journal of cardiac failure.

[6]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[7]  J. Hollander,et al.  B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure: Analysis From Breathing Not Properly (BNP) Multinational Study , 2002, Circulation.

[8]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[9]  M. Davies,et al.  Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations , 2002, BMJ : British Medical Journal.

[10]  M. Pfeffer,et al.  New Therapeutic Options in Congestive Heart Failure: Part II , 2002, Circulation.

[11]  L. Fisher,et al.  Surrogate end points in heart failure. , 2002, Journal of the American College of Cardiology.

[12]  Marc A Pfeffer,et al.  New therapeutic options in congestive heart failure: Part I. , 2002, Circulation.

[13]  H. Naruse,et al.  Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. , 2002, The American journal of cardiology.

[14]  M. Vogeser,et al.  Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[15]  M. Kinoshita,et al.  High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.

[16]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[17]  W. R. Taylor,et al.  Plasma norepinephrine and atrial natriuretic peptide in heart failure: influence of felodipine in the third Vasodilator Heart Failure Trial. V-HeFT III investigators. , 2000, Journal of cardiac failure.

[18]  S. Nakatani,et al.  Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. , 2000, Journal of cardiac failure.

[19]  R. McKelvie,et al.  Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study. , 2000, Circulation.

[20]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[21]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[22]  J. Cohn,et al.  Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. , 1999, Journal of cardiac failure.

[23]  R. Doughty,et al.  Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 1999, Circulation.

[24]  H. Hense,et al.  Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. , 1998, Journal of the American College of Cardiology.

[25]  M. B. Perryman,et al.  Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. , 1997, Circulation.

[26]  C R Benedict,et al.  Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. , 1996, Circulation.

[27]  K. Swedberg,et al.  The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. , 1996, American heart journal.

[28]  S. Yusuf,et al.  Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction , 1995 .

[29]  B. Greenberg,et al.  Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators. , 1995, The American journal of cardiology.

[30]  J. Rouleau,et al.  Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. , 1994, Journal of the American College of Cardiology.

[31]  S. Yusuf,et al.  Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. , 1994, Journal of the American College of Cardiology.

[32]  W. Edwards,et al.  Endothelin in human congestive heart failure. , 1994, Circulation.

[33]  R. Re,et al.  Tissue angiotensin system in cardiovascular medicine. A paradigm shift? , 1994, Circulation.

[34]  J. Cohn,et al.  Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure Relations to Survival and the Effects of Therapy in V‐HeFT II , 1993, Circulation.

[35]  M. A. Plant.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality , 1991 .

[36]  K. Inouye,et al.  Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. , 1991, The Journal of clinical investigation.

[37]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[38]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[39]  J. Cohn,et al.  Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. , 1982, The American journal of cardiology.

[40]  J. Staessen,et al.  Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. , 1981, The Journal of endocrinology.

[41]  J. Izzo,et al.  Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. , 1981, Life sciences.

[42]  F. Leenen,et al.  Atenolol and chlorthalidone on blood pressure, heart rate, and plasma renin activity in hypertension , 1979, Clinical pharmacology and therapeutics.

[43]  J. A. Thomas,et al.  Plasma norepinephrine in congestive heart failure. , 1978, The American journal of cardiology.

[44]  J. Laragh,et al.  Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. , 1972, The New England journal of medicine.

[45]  T. Diperri,et al.  Aldosterone in congestive heart failure. , 1959, Acta medica Scandinavica.